Objective To review recent clinical pharmacokinetic and pharmacodynamic data to optimize
dosing regimens for polymyxin B and colistin for treatment of infections due to A. baumannii …

Combinations of antimicrobial agents are often used in the management of infectious
diseases. Antimicrobial agents used as part of combination therapy are often selected …

Carbapenem-resistant Acinetobacter baumannii (CRAB) constitutes an increasing problem
worldwide. CRAB bacteremia is associated with a high fatality rate and its optimal treatment …

Introduction: Acinetobacter baumannii (AB) is a multidrug-resistant pathogen commonly
associated with nosocomial infections. The resistance profile and ability to produce biofilm …

Highlights•Currently the best alternative to carbapenems for ESBL related infections are
BLBLI.•Combination therapy is advisable for CRE infections.•Microbiological adequacy not …

Polymyxin combination therapy is increasingly used clinically. However, systematic
investigations of such combinations are a relatively recent phenomenon. The emerging …

Acinetobacter baumannii is a drug-resistant Gram-negative pathogen increasingly causing
hospital-acquired infections in critically ill patients. In this review, we summarize the current …

Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) Gram-
negative bacteria (GNB) has emerged as an important and intractable clinical problem. This …

Multidrug-resistant (MDR) Acinetobacter baumannii presents a critical challenge to human
health worldwide and polymyxins are increasingly used as a last-line therapy. Due to the …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) is resistant to
major antibiotics such as penicillin, cephalosporin, fluoroquinolone and aminoglycoside …